Index

a

abortifacient disease 70–1
accessibility of vaccines 183–5
adaptive immunity 11–12
adjuvants 14–17, 106–7, 124–5
alum 14, 106
Anaplasma marginale (bovine anaplasmosis) 80–1, 87–9, 92
animal trypanosomiasis 78–9, 82–5, 90–1
anthrax vaccines 371–81
  adverse reactions 378
  Carbosap 372
  combinations 375
  edible 373
  immune response 373–4
  manufacturers 378
  outbreak control 375–7
  outbreaks in vaccinated animals 377–8
  Pasteur's 371–2
  postvaccination monitoring 377
  quality assurance and control 374
  recombinant 373
  specification 374
  Sterne 372–3
  vaccination strategy 374–5
  wildlife 377
antibiotics
  resistance 6, 67
  vaccine manufacture 150
anti-tick vaccines 93–4, 103
association 174–5
audit 140–1
autogenous bacterial vaccines 66
avian influenza vaccines 7, 229–51
  adverse reactions 244
  combinations 242–3
  contraindications 245
  control strategy 229–30
  doses used in field 231, 235–7
  duration of immunity 237
  immune response 237
  inactivated 231
  licensed technologies 231, 232–5
  live 231
  manufacturers 244–5
  outbreak control 243
  outbreaks in vaccinated animals 244
  postvaccination monitoring 243–4
  quality assurance and control 239
  specification 237–9
  subunit 231
  vaccination strategy 239–42
avian mycoplasmoses 73

b

B cells 11, 12
babesiosis (*Babesia* spp.) 80, 86–7, 91–2
Bacillus anthracis 371
backyard production 6–7
bacterial seed 151, 153
bacterial vaccines 63–76
batch testing 162
batch-to-batch consistency 168
bath vaccination 114, 115, 116
bluetongue vaccines 263–81
  combinations 270
  disabled infectious single animal (DISA) 272
  disabled infectious single cycle (DISC) 271
  duration of immunity 273
  economic costs 264–5, 266, 269
  genetically modified organisms 272
  immune response 272–3
  inactivated 266, 270–1
  live attenuated 265–6
  postvaccination monitoring 270
  quality control 269–70
  registered 266, 267–8
  reverse genetics 271
  serotyped 271
  specification 270
  subunit (VP2) 271
  vaccination strategy 273–4
  vector-based 271
  virus-like particles 271
booster efficacy 172
bovine anaplasmosis 80–1, 87–9, 92
bovine babesiosis 80, 86–7, 91–2
bovine leptospirosis 71
brucellosis vaccines 6, 71, 295–316
  B. abortus Δ*pgm* 305
  B. abortus 45/20 303
  B. abortus RB51 303–4
  B. abortus S19 297–302
  B. melitensis B115 305
  B. melitensis Rev1 297–302
  "brucellosis (officially) free" status 308
  control programs 308–10
  DIVA 302, 305
  economic costs 295–6
  eradication programs 307–8
  human disease 295, 296
  mass (whole herd) vaccination 308–10
  protection against abortion 296–7
  protein-deleted mutants 305
  recombinant 306–7
  rough 302–5
  safety 297
  smooth 297–302
  vaccination strategy 307–10
  xenogenic antigen-tagged 305–6
  young replacement vaccination 308

Veterinary Vaccines: Principles and Applications, First Edition. Edited by Samia Metwally, Gerrit Viljoen, and Ahmed El Idrissi.

c

campaign production 143
capripox vaccines 383–97
  adverse reactions 392–3
  disease control 390–1
  effectiveness 392
  immune response 389–90
  inactivated 386, 389
  KSGPV O-240/O-180 386
  live attenuated 386
  manufacturers 387–9
  outbreak control 391
  postvaccination monitoring 392
  quality assurance and control 390
  recombinant 391
  RM65 386
  vaccination strategy 390–1
Carbosap vaccine 372
caseous lymphadenitis 74
CD4 cells 12–13
CD8 cells 13
cell banks 152, 153
cell lines 151
cell-mediated immunity 12–14
central memory T cells 13
challenge test 165, 171–2
chimeric viruses 121–2
chlamydiosis 70–1
classic swine fever vaccines 327–34
  adverse reactions 333
  baculovirus-expressed E2 protein 328
  chimeric pestivirus CP7_E2Alf 328, 329
  combinations 330
  contraindications 331
  endemic settings 330
  immune response 328–9
  manufacturers 333
  marker 328
  modified live viruses 327–8
  outbreak control 330–1
  outbreaks in vaccinated animals 332–3
  postvaccination monitoring 332
  quality assurance and control 329
  specification 329
  subunit 328
  vaccination strategy 329–30
  wild boar 331–2
clostridial disease 69
colibacillosis 69
combination vaccines 67, 173–4
commercialization 181–2
Committee of the Americas for Veterinary Medical Products (CAMEVET) 30–1
compatibility of vaccines 174–5
confidence gaps 45
conjugate vaccines 66
contagious agalactia 73
contagious bovine pleuropneumonia vaccines 72, 317–26
  combinations 323
  contraindications 323
  immune response 319–20
  manufacturers 324
  outbreak control 323
  outbreaks in vaccinated animals 324
  postvaccination monitoring 323
  quality assurance and control 321–2
  specification 320–1
  T1/44 and T1sr 318–19
  vaccination strategy 322–3
  Willems reaction 318, 324
contagious caprine pleuropneumonia 72–3
cooperative programs 184–5
costs of vaccines 181, 183
coverage of vaccines 43
cowdriosis (heartwater) 81, 89–90, 92–3
coxiellosis 70
CpG oligodeoxynucleotides 14, 125
Culicoides midges 264

d

development of vaccines 119–34, 180–1
diluents 151
dip vaccination 115–16
disabled infectious single animal (DISA) vaccine 272
disabled infectious single cycle (DISC) vaccine 121, 271
distribution networks 183
DIVA vaccines 20–1, 119, 302, 305, 345
DNA vaccines 56, 57–8, 89, 103–4, 122–3, 164, 165, 211, 259
documentation
  vaccination 42
  vaccine manufacture 140, 149, 157
duration of immunity 172

e

East Coast fever 79–80, 85
echinococcosis 103
effectiveness of vaccines 44–5
effector memory T cells 14
efficacy (VE) 19–20, 38–9, 164, 171–5, 196–7
Ehrlichia ruminantium 81
emergency vaccination 40–1, 189
emerging diseases 6–7
endotoxin content 163
enteric disease vaccines 68–70
enteropathogenic *E. coli* (EPEC) 69
enterotoxigenic *E. coli* (ETEC) 69
environmental risk assessment 170, 171
Escherichia coli 69
European Medicines Agency (EMA) 29, 35
European Pharmacopoeia 29, 35
European Union regulations 191
extraneous agent testing 163

f

field efficacy 44–5
field studies 171, 173
final product testing 161–6
fish vaccines 19, 113–18
Food and Agriculture Organization (FAO) 27, 32, 35
food production 4–6
food safety 7
foot and mouth disease vaccines 5–6, 207–27
  adverse reactions 218
  carriers 209
  combinations 217–18
  DNA 211
  immune response 211–12
  killed 209, 210
  live attenuated 210
  manufacturers 220–4
  mass vaccination 216–17
  outbreaks in vaccinated animals 218
  peptide 211
  postvaccination monitoring 218
  progressive control pathway 209
  quality assurance and control 213–14

reactive vaccination 214–16
recombinant 211
regional virus pools 207
ring vaccination 214
risk-based vaccination 214
schedule 210
selection 212
specification 212–13
forecasting 183–4
Freund's adjuvant 14

g

gene-deleted vaccines 53, 121
genetically modified organisms 170, 272
ghost vaccines 124
Global Alliance for Livestock Veterinary Medicine (GALVmed) 27, 190–1
goat pox *see* capripox vaccines

h

Health for Animals 27–8
heartwater 81, 89–90, 92–3
hemagglutination inhibition tests 165
hemorrhagic septicemia 72
herd immunity 18, 38, 39, 43
herd immunity threshold 43, 216–17
hydrogen peroxide inactivation 128

i

identity testing 162
immune conversion 11–14
immune correlates of protection 20
immune-stimulating complexes (ISCOMs) 17, 125
immunoglobulins 12
impact measurement 44–5
implementing vaccination 42, 43–4
in ovo vaccination 19
in-process tests 154–6, 163
inactivated vaccines
bacterial 64, 66
inactivation tests 155, 163
potency tests 164, 165
protozoal and rickettsial 82, 90
viral 53–5, 57
induced immunity 17–18
innate immunity 11
Inter-American Cooperation Group on Animal Health 30
Inter-American Institute for Cooperation on Agriculture (IICA) 30, 35
International Alliance of Biological Standardization (IABS) 31
International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) 31
intranasal administration 18–19
irradiated vaccines 126–7

j

Johne's disease 69–70

l

legislation 167–8, 180–1
leptospirosis 71
licensing
vaccine manufacturing facilities 139–40
vaccines 167–77, 180–1
live vaccines
bacterial 64
parasites 101–2
potency tests 164, 165
protozoal and rickettsial 82, 85–7, 88, 90
safety requirements 170
viral 52–3, 57
lumpy skin disease *see* capripox vaccines

m

manganese peptide complex 127
Mannheimia haemolytica 72
manufacture of vaccines
campaign production 143
documentation 140, 149, 157
facilities 137–45, 181
final product testing 161–6
local production 142–3, 185
quality control and assurance 141–2, 147–59
safety 138–9, 163–4, 165
market size 181
marketing 183
marketing authorization 167
master seeds 152–4
maternally-derived antibodies 173, 339
memory B cells 12
memory T cells 13–14
minor species or minor use (MUMS) vaccines 175
monitoring
strategic vaccines 197–8
vaccination implementation 43–4
monophosphoryl lipid A 14
montanides 14
mucosal administration 17, 18–19
multistrain dossier 175
multivalent vaccines 173–4
Mycoplasma vaccines 72–3

n

National Institute for Biological Standards and Control (NIBSC) 32
National Veterinary Stockpile 7
native antigen vaccines 102
Newcastle disease vaccines 335–53
adverse reactions 348–9
antibody/antigen complex 337
combinations 346
contraindications 346–7
DIVA 345
eradication of disease 345
human infection 348–9
immune response 337–9
inactivated 337
live vectored 336–7
manufacturers 349, 350
maternal-derived antibody 339
"minor species" 345
outbreak control 346
outbreaks in vaccinated animals 348
postvaccination monitoring 347–8
preventive vaccination 345
quality assurance and control 340–1
recombinant 336–7
routine vaccination 345
specification 339–40
"traditionally attenuated" live 336
turkeys 345
vaccination strategy 341–5
nomadic herds 40

o

Official Control Authority Batch Release and Official Batch Protocol Review (OCABR/OBPR) 29–30
OIE *see* World Organization for Animal Health

onset of immunity 172
Organization for Economic Co-operation and Development (OECD) 31, 35

p

packaging 182
Pan African Veterinary Vaccine Centre (PANVAC) 28–9
Pan American Health Organization (PAHO) 30
parasite vaccines 101–11
paratuberculosis 69–70
particulate vaccines 17, 125
passive immunity 17
pattern recognition receptors 14, 125
peptide vaccines 56, 123, 211
performance-based standards 141
peste des petits ruminants vaccines 283–94
  combinations 287
  duration of immunity 286
  immune response 285–6
  live attenuated 283, 285
  manufacturers 288, 289–91
  quality assurance and control 286
  specification 286
  vaccination campaigns 287–8
  vaccination strategy 286–7
pharmacovigilance 183
plant-based vaccines 56, 125–6
policy issues 8
polyphosphazenes 125
polysaccharide vaccines 123
porcine reproductive and respiratory syndrome vaccines 355–70
  adverse reactions 362–3
  combinations 361–2
  contraindications 362
  control measure 360–1
  herd status classification 360
  immune response 357–8
  killed virus 356–7
  live virus vectors 357
  modified live virus 356
  mucosal 357
  outbreak control 362
  outbreaks in vaccinated animals 362
  postvaccination monitoring 362
  quality assurance and control 359–60
  reverse genetics 357
  specification 358
postsales support 183
postvaccination immunity 43
potency tests 164–5
pregnancy, passive immunity 17
presales support 183
preservatives 150–1
process controls 141–2
proficiency tests 156–7
protozoal vaccines 77–99
psoralen inactivation 127–8

q

Q fever 70
quality control and assurance 141–2, 147–59, 196–7

r

R_0 43
rabies vaccines 399–413
  adjuvants 401
  adverse reactions 408
  availability 408–9
  boosters 404, 406
  edible 402
  fixed virus 401
  human infection 405
  immune response 402–4
  inactivated 401
  live 401
  livestock vaccination 406
  postexposure prophylaxis 406–7
  postvaccination monitoring 407–8
  quality assurance and control 405–6
  rabies induction 408
  recombinant 401
  specification 404
  street virus 401
  vampire bats 407
  wildlife 405
raw materials 149–52
recombinant vaccines 122, 211, 306–7, 336–7, 373, 391, 401
  bacterial 66–7, 122
  parasites 102–3
  protozoal and rickettsial 82, 85
  viral 53, 122
record-keeping
  implementing vaccination 42
  vaccine manufacture 140–1
reference laboratories 32–3
registration
  vaccine manufacturing facilities 139–40
  vaccines 167–77, 180–1
residual toxicity tests 163
residue studies 171
respiratory diseases 71–2
respiratory syncytial virus vaccine 12
reverse genetics 120–1, 258–9, 271, 357
reverse vaccinology 128
rickettsial vaccines 77–99
Rift Valley fever vaccines 7, 53, 253–62
  Clone 13 257
  DNA 259
  human infection 243–4
  inactivated 256–7
  live MP-12 258
  live Smithburn 256
  NSs and NSm proteins 254–6
  reverse genetics 258–9
  specification 259
  subunit 259
  vaccination strategy 257–8
rinderpest eradication 3
RNA vaccines 123

s

safety
  live vaccines 170
  manufacture of vaccines 138–9, 163–4, 165
  registration of vaccines 169–71
  strategic vaccines 196–7
salmonellosis 68
saponins 17
seed lots 152–4
serum 151
sheep pox *see* capripox vaccines
shrimp vaccines 116
Smithburn vaccine 256
stability testing 155–6, 168–9
standardization of vaccines 25–36
starting materials 149–52
sterility of vaccines 152, 155, 162
Sterne vaccine 372–3
storage of vaccines 156, 197–8
strangles 74
strategic vaccine reserves (banks) 7–8, 185, 189–203

strategies of vaccination 39–41
subsidized vaccines 184–5
subunit vaccines 123, 231, 259, 271, 328
  bacterial 66
  parasites 104
  potency tests 164
  protozoal and rickettsial 82, 85, 86, 87, 88, 90
  viral 55, 57
synthetic peptide vaccines 56, 123, 211
systemic administration 18

t

T cells 11, 12–13
Taenia solium 6, 103
technical support 183
temperature-controlled storage 156
Theileria annulata 79–80, 85–6, 91
Theileria parva 79–80, 85, 91
tick vaccines 93–4, 103
tissue resident memory T cells 14
toll-like receptors 125
toxoid vaccines 66
transmissible spongiform encephalopathy (TSE) 151–2
tropical theileriosis 79–80, 85–6, 91
trypanosomiasis (*Trypanosoma* spp.) 78–9, 82–5, 90–1
trypanotolerance 91

v

vaccinate to die 215
vaccinate to live 192, 215
vaccination strategies 39–41
vaccine-associated enhanced respiratory disease 12
vaccine banks 7–8, 185, 189–203
vaccine delivery systems 18–19
vampire bats 407
vector vaccines 53, 122
Veterinary Batch Release Network (VBRN) 30
viral seed 151, 153
viral vaccines 51–61
virus-like particles 17, 55, 123–4, 271

w

water-in-oil emulsions 14
West Nile virus vaccine 4
whole cell bacterin vaccines 66
wildlife vaccines 19, 331–2, 377, 405
Willems reaction 318, 324
working seeds 152–4
World Health Organization (WHO) 28, 32–3, 34–5
World Organization for Animal Health (OIE) 26–7, 32, 33–4, 190

z

zoonotic diseases 6–7